Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Evaluation of the Addition of the Resource Intervention to Support Equity (RISE) to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma

NCT06831552 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06831552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06831552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Evaluation of the Addition of the Resource Intervention to Support Equity (RISE) to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
April 30, 2025
Completion date
June 1, 2029
Enrollment
84 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk neuroblastoma, neuroblastoma